TCGA-CR-7389-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- APICAL_SURFACE+0.290
- UV_RESPONSE_DN+0.290
- ANGIOGENESIS+0.280
- HEDGEHOG_SIGNALING+0.270
- KRAS_SIGNALING_UP+0.250
- BILE_ACID_METABOLISM+0.230
- APICAL_JUNCTION+0.220
- NOTCH_SIGNALING+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.670
- E2F_TARGETS-0.630
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.540
- DNA_REPAIR-0.470
- OXIDATIVE_PHOSPHORYLATION-0.380
- MTORC1_SIGNALING-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.260
- PI3K_AKT_MTOR_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.875 |
| 2 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.860 |
| 3 | MNG792 | — | — | 0.857 |
| 4 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.854 |
| 5 | SRR8518453 | — | F | 0.850 |
| 6 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.847 |
| 7 | BS_GV3NZ9QD | EPN | EPN Tumor | 0.844 |
| 8 | TCGA-CR-7391-01A-11R-2016-07 | — | — | 0.840 |
| 9 | C3N-02193 | — | cohortA1 | 0.838 |
| 10 | C3L-03268 | — | cohortA1 | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |